HOME >> BIOLOGY >> NEWS
New Medication Means New Choices For Families Dealing With Alzheimers Disease

Hershey, Pa. -- A new study from Penn State's College of Medicine finds that when medication for Alzheimer's disease is offered to all patients, family members of patients in the early stages of Alzheimer's are the most likely to accept available treatment.

"When dealing with this terrible disease, families are faced with many extremely difficult decisions. One of those decisions is whether or not to treat their ill family member with this relatively new drug, that doesn't stop the disease, but slows the progression of the disease," says Paul Kettl, M.D., associate professor of psychiatry and acting chair of psychiatry at Penn State. Kettl is also chief of psychiatry with the Penn State Geisinger Health System in Hershey, Pa.

The results of the one-year study titled, "Family Treatment Decisions in Alzheimer's Disease," was presented today (June 3) at the American Psychiatric Association meeting in Toronto.

Kettl studied 60 patients with Alzheimer's disease who were admitted consecutively to the inpatient psychiatry unit at Hershey Medical Center. The one-year study asked families whether or not they wanted the patient to be treated with the drug donepezil or vitamin E. Both treatments do not stop the disease but significantly slow the progress of the disease. Donepezil has been widely prescribed by physicians for about a year.

"There were 28 people in the treatment group and 32 people in the non-treatment group. We found there was no difference based on age or sex," says Kettl. "The difference in treatment decisions was determined more by how far the disease had progressed. For patients who were in the early stages of the disease and often were cared for at home, families overwhelmingly chose to treat the patient. For those patients who lived in a nursing home and the disease was fairly advanced, families chose to withhold the treatment."

Kettl says these kinds of difficult ethical questions will have to
'"/>

Contact: Leilyn Perri
lperri@psghs.edu
717-531-8604
Penn State
3-Jun-1998


Page: 1 2

Related biology news :

1. Medication reconciliation, pharmacist involvement vital to reducing medication errors, study finds
2. Possible Dangers Of Taking Over-The-Counter Medications For Hepatitis C Patients
3. Common Anti-Viral Medication Prevents Severe Eye Herpes
4. Study Reviews Medication Use In Elderly Cardiac Patients After Discharge
5. Material Choices For The Chemical Industry
6. Families with severe form of bipolar disorder help scientists narrow the search for disease genes
7. Families with two or more children with autism sought for $10.2 million study
8. Sudden Cardiac Death May Run In Families
9. Vastly Different Virus Families May Be Related
10. Dealing with reams of data
11. New theory of cell death proposed in UCSB Alzheimers research

Post Your Comments:
(Date:10/30/2014)... a $1.04 million grant from the U.S. Army ... osteoarthritis using a patient,s own stem cells, spurred ... polymers., Liping Tang, a bioengineering professor and interim ... is primarily focused on helping soldiers who are ... if we inject microscaffolding that we,ve developed into ...
(Date:10/30/2014)... North Carolina State University researchers have developed a suite ... between dogs and humans, which has applications in everything ... our pets. , "We,ve developed a platform for computer-mediated ... to new avenues for interpreting dogs, behavioral signals and ... Dr. David Roberts, an assistant professor of computer science ...
(Date:10/29/2014)... In the largest study of its kind to date, ... genes that heighten the risk for autism. Joseph Buxbaum, ... York City, Mark Daly, Ph.D., Broad Institute of Harvard ... DNA samples from affected children, parents and unrelated people. ... to contribute to the risk for autism spectrum disorder ...
Breaking Biology News(10 mins):UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2New tech aims to improve communication between dogs and humans 2
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) ... Flavored, Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, ... Forecast to 2018," defines and segments the dairy ... of revenue and volume for plant-based dairy alternative ... reach $14 Billion by 2018 with the Asia-Pacific ...
(Date:10/31/2014)... ORLANDO, Fla. , Oct. 31, 2014 /PRNewswire/ ... firm owned by Tavistock Group, celebrated the groundbreaking of ... Nona Medical City. The 92,000-square-foot, ... Central Florida designed specifically ... Located in the heart of the 650-acre Lake ...
(Date:10/30/2014)...  Ardelyx, Inc. (NASDAQ: ARDX ), ... and metabolic diseases, today announced that it will ... November 6, 2014. Following the announcement, the Ardelyx ... and webcast at 4:30pm ET to review the ... The live webcast can be accessed ...
(Date:10/30/2014)... BOSTON, MA (PRWEB) October 30, 2014 ... communication and collaboration provider, offers Office 365 end ... software into a complete phone system by adding ... Office 365 (O365) includes Lync Online, a communication ... to Lync calls. With hosted voice, O365 becomes ...
Breaking Biology Technology:Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3
Cached News: